| Code | CSB-RA001950MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Lecanemab, targeting amyloid precursor protein (APP) and its pathogenic cleavage products. APP is a transmembrane protein that undergoes sequential proteolytic processing to generate amyloid-beta (Aβ) peptides, which accumulate as soluble protofibrils and insoluble plaques in the brain. These Aβ aggregates are a pathological hallmark of Alzheimer's disease and contribute to neurodegeneration through multiple mechanisms including synaptic dysfunction, neuroinflammation, and neuronal loss. APP processing and Aβ accumulation represent critical pathways in Alzheimer's disease pathogenesis and are key therapeutic targets.
Lecanemab is a humanized IgG1 monoclonal antibody with preferential binding to soluble Aβ protofibrils, which are considered particularly neurotoxic species in Alzheimer's disease progression. This biosimilar antibody serves as a valuable research tool for investigating Aβ biology, studying mechanisms of amyloid-mediated neurotoxicity, evaluating protofibril formation and clearance pathways, and developing novel therapeutic strategies for Alzheimer's disease and related neurodegenerative disorders. It enables researchers to explore antibody-mediated approaches to amyloid pathology in preclinical models.
There are currently no reviews for this product.